The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Self-citationOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Self-citationPrevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
Self-citationKappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Feys, P., Lamers, I., Francis, G., Benedict, R., Phillips, G., LaRocca, N., Hudson, L. D., Rudick, R., & Multiple Sclerosis Outcome Assessments Consortium (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517690824 · Cited by 516
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1496 · Cited by 475
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results
Li, D. K. B., Zhao, G. J., Paty, D. W., & the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1505 · Cited by 458
Lublin, F., Miller, D. H., Freedman, M. S., Cree, B. A. C., Wolinsky, J. S., Weiner, H., Lubetzki, C., Hartung, H.-P., Montalban, X., Uitdehaag, B. M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01314-8 · Cited by 448
Self-citation
Cited by
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459
Treatment of multiple sclerosis — success from bench to bedside
Tintore, M., Vidal-Jordana, A., & Sastre-Garriga, J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0082-z · Cited by 343
Epidemiology and treatment of multiple sclerosis in elderly populations
Vaughn, C. B., Jakimovski, D., Kavak, K. S., Ramanathan, M., Benedict, R. H. B., Zivadinov, R., & Weinstock-Guttman, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0183-3 · Cited by 306
on behalf of the MAGNIMS study group, Sastre-Garriga, J., Pareto, D., Battaglini, M., Rocca, M. A., Ciccarelli, O., Enzinger, C., Wuerfel, J., Sormani, M. P., Barkhof, F., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0314-x · Cited by 273
Self-citation
Metadata
- Authors
- Kapoor, R., Ho, P.-R., Campbell, N., Chang, I., Deykin, A., Forrestal, F., Lucas, N., Yu, B., Arnold, D. L., Freedman, M. S., Goldman, M. D., Hartung, H.-P., Havrdová, E. K., Jeffery, D., Miller, A., Sellebjerg, F., Cadavid, D., Mikol, D., Steiner, D., Bartholomé, E., D'Hooghe, M., Pandolfo, M., Van Wijmeersch, B., Bhan, V., Blevins, G., Brunet, D., Devonshire, V., Duquette, P., Freedman, M., Grand'Maison, F., Jacques, F., Lapierre, Y., Lee, L., Morrow, S., Yeung, M., Dufek, M., Havrdová, E. K., Kanovsky, P., Stetkarova, I., Talabova, M., Frederiksen, J., Kant, M., Petersen, T., Ravnborg, M., Sellebjerg, F., Airas, L., Elovaara, I., Eralinna, J.-P., Sarasoja, T., Al Khedr, A., Brassat, D., Brochet, B., Camu, W., Debouverie, M., Laplaud, D., Lebrun Frenay, C., Pelletier, J., Vermersch, P., Vukusi, S., Baum, K., Berthele, A., Faiss, J., Flachenecker, P., Hohlfeld, R., Krumbholz, M., Lassek, C., Maeurer, M., Meuth, S., Ziemssen, T., Hardiman, O., McGuigan, C., Achiron, A., Karussis, D., Bergamaschi, R., Morra, V. B., Comi, G., Cottone, S., Grimaldi, L., Mancardi, G. L., Massacesi, L., Nocentini, U., Salvetti, M., Scarpini, E., Sola, P., Tedeschi, G., Trojano, M., Zaffaroni, M., Frequin, S., Hupperts, R., Killestein, J., Schrijver, H., Van Dijl, R., van Munster, E., Czarnecki, M., Drozdowski, W., Fryze, W., Hertmanowska, H., Ilkowski, J., Kaminska, A., Klodowska-Duda, G., Maciejowski, M., Motta, E., Podemski, R., Potemkowski, A., Rog, T., Selmaj, K., Stelmasiak, Z., Stepien, A., Tutaj, A., Zaborski, J., Boyko, A., Chefranova, Z., Evdoshenko, E., Khabirov, F., Sivertseva, S., Yakupov, E., Alvarez Cermeño, J. C., Escartin, A., Fernandez, O. F., Garcia-Merino, A., Hernandez Perez, M. A., Ayuso, G. I., Lallana, J. M., Gairin, X. M., Oreja-Guevara, C., Saiz Hinarejos, A., Gunnarsson, M., Lycke, J., Martin, C., Piehl, F., Roshanisefat, H., Sundstrom, P., Duddy, M., Gran, B., Harrower, T., Hobart, J., Kapoor, R., Lee, M., Mattison, P., Nicholas, R., Pearson, O., Rashid, W., Rog, D., Sharrack, B., Silber, E., Turner, B., Williams, A., Woolmore, J., Young, C., Bandari, D., Berger, J., Camac, A., Cohan, S., Conway, J., Edwards, K., Fabian, M., Florin, J., Freedman, S., Garwacki, D., Goldman, M., Harrison, D., Herrman, C., Huang, D., Javed, A., Jeffery, D., Kamin, S., Katsamakis, G., Khatri, B., Langer-Gould, A., Lynch, S., Mattson, D., Miller, T., Miravalle, A., Moses, H., Muley, S., Napier, J., Nielsen, A., Pachner, A., Pardo, G., Picone, M., Robertson, D., Royal, W., Sheppard, C., Thrower, B., Twyman, C., Waubant, E., Wendt, J., Yadav, V., Zabad, R., & Zarelli, G.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 17
- Issue
- 5
- Pages
- 405-415
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2793526309
- Cited by
- 333
- References
- 29
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. https://app.cochat.ai/papers/10.1016/s1474-4422(18)30069-3
- The paper
- Kapoor, R., Ho, P.-R., Campbell, N., Chang, I., Deykin, A., Forrestal, F., Lucas, N., Yu, B., Arnold, D. L., Freedman, M. S., Goldman, M. D., Hartung, H.-P., Havrdová, E. K., Jeffery, D., Miller, A., Sellebjerg, F., Cadavid, D., Mikol, D., Steiner, D., . . . Zarelli, G. (2018). Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(18)30069-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.